Update on the use of trilostane in dogs

Julie Denise Lemetayer, Shauna Blois

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.

Original languageEnglish (US)
Pages (from-to)397-407
Number of pages11
JournalCanadian Veterinary Journal
Volume59
Issue number4
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

hyperadrenocorticism
Adrenocortical Hyperfunction
Dogs
dogs
cortisol
dosage
hydroxysteroid dehydrogenases
alopecia
hypertension
steroids
Hydrocortisone
mechanism of action
3-Hydroxysteroid Dehydrogenases
adverse effects
therapeutics
synthesis
duration
Thrombophilia
trilostane
monitoring

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Lemetayer, J. D., & Blois, S. (2018). Update on the use of trilostane in dogs. Canadian Veterinary Journal, 59(4), 397-407.

Update on the use of trilostane in dogs. / Lemetayer, Julie Denise; Blois, Shauna.

In: Canadian Veterinary Journal, Vol. 59, No. 4, 01.04.2018, p. 397-407.

Research output: Contribution to journalReview article

Lemetayer, JD & Blois, S 2018, 'Update on the use of trilostane in dogs', Canadian Veterinary Journal, vol. 59, no. 4, pp. 397-407.
Lemetayer JD, Blois S. Update on the use of trilostane in dogs. Canadian Veterinary Journal. 2018 Apr 1;59(4):397-407.
Lemetayer, Julie Denise ; Blois, Shauna. / Update on the use of trilostane in dogs. In: Canadian Veterinary Journal. 2018 ; Vol. 59, No. 4. pp. 397-407.
@article{d603f2cef54e4d99a9b1207152407e00,
title = "Update on the use of trilostane in dogs",
abstract = "Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.",
author = "Lemetayer, {Julie Denise} and Shauna Blois",
year = "2018",
month = "4",
day = "1",
language = "English (US)",
volume = "59",
pages = "397--407",
journal = "Canadian Veterinary Journal",
issn = "0008-5286",
publisher = "Canadian Veterinary Medical Association",
number = "4",

}

TY - JOUR

T1 - Update on the use of trilostane in dogs

AU - Lemetayer, Julie Denise

AU - Blois, Shauna

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.

AB - Many articles published in the past few years have contributed to a better understanding of the use of trilostane in dogs. Trilostane is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase, the enzyme essential for synthesis of Cortisol and all other steroids. Trilostane is reported to be safe and effective in the treatment of pituitary-dependent hyperadrenocorticism (HAC), adrenal-dependent HAC, and alopecia X. While trilostane controls most of the clinical signs associated with HAC, abnormalities such as hypertension, hypercoagulability, and proteinuria may persist despite therapy. Because the duration of Cortisol suppression after a dose of trilostane is often less than 12 hours, many dogs with HAC could benefit from low dose trilostane treatment every 12 hours. Many controversies regarding trilostane still exist. This review provides a comprehensive commentary on trilostanes indications, mode of action, dose, monitoring, efficacy, and adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=85048220216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048220216&partnerID=8YFLogxK

M3 - Review article

C2 - 29606727

AN - SCOPUS:85048220216

VL - 59

SP - 397

EP - 407

JO - Canadian Veterinary Journal

JF - Canadian Veterinary Journal

SN - 0008-5286

IS - 4

ER -